Rock Springs Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $25.5M | Sell |
1,218,773
-48,468
| -4% | -$1.09M | 1.5% | 20 |
|
|
2025
Q4 | $29.1M | Buy |
1,267,241
+20,900
| +2% | +$687K | 1.49% | 21 |
|
|
2025
Q3 | $37.5M | Sell |
1,246,341
-144,731
| -10% | -$4.34M | 2.19% | 13 |
|
|
2025
Q2 | $50.6M | Sell |
1,391,072
-3,362
| -0.2% | -$121K | 3.15% | 6 |
|
|
2025
Q1 | $50.5M | Sell |
1,394,434
-345,379
| -20% | -$14.4M | 2.89% | 8 |
|
|
2024
Q4 | $73.2M | Sell |
1,739,813
-238,459
| -12% | -$11.8M | 2.79% | 9 |
|
|
2024
Q3 | $110M | Buy |
1,978,272
+54,200
| +3% | +$2.76M | 3.58% | 5 |
|
|
2024
Q2 | $79.1M | Buy |
1,924,072
+149,134
| +8% | +$6.37M | 2.38% | 8 |
|
|
2024
Q1 | $82.9M | Buy |
1,774,938
+20,900
| +1% | +$986K | 2.1% | 12 |
|
|
2023
Q4 | $83.9M | Buy |
1,754,038
+277,597
| +19% | +$10.8M | 2.06% | 15 |
|
|
2023
Q3 | $52.6M | Buy |
1,476,441
+92,172
| +7% | +$3.65M | 1.41% | 25 |
|
|
2023
Q2 | $63.9M | Buy |
1,384,269
+47,868
| +4% | +$2.22M | 1.52% | 23 |
|
|
2023
Q1 | $53.6M | Buy |
1,336,401
+46,122
| +4% | +$1.98M | 1.28% | 28 |
|
|
2022
Q4 | $59.8M | Buy |
1,290,279
+102,287
| +9% | +$4.02M | 1.44% | 24 |
|
|
2022
Q3 | $49.2M | Buy |
1,187,992
+94,962
| +9% | +$4.88M | 1.27% | 24 |
|
|
2022
Q2 | $65.2M | Buy |
1,093,030
+64,921
| +6% | +$3.99M | 1.9% | 11 |
|
|
2022
Q1 | $74.7M | Buy |
1,028,109
+144,188
| +16% | +$10M | 1.88% | 16 |
|
|
2021
Q4 | $74.3M | Buy |
883,921
+82,812
| +10% | +$6.74M | 1.72% | 16 |
|
|
2021
Q3 | $72.3M | Buy |
801,109
+336,109
| +72% | +$30.4M | 1.52% | 20 |
|
|
2021
Q2 | $44.3M | Buy |
465,000
+15,000
| +3% | +$1.56M | 0.88% | 34 |
|
|
2021
Q1 | $51.2M | Sell |
450,000
-116,500
| -21% | -$15.9M | 1.12% | 29 |
|
|
2020
Q4 | $78.4M | Sell |
566,500
-10,341
| -2% | -$1.23M | 1.66% | 14 |
|
|
2020
Q3 | $47.4M | Sell |
576,841
-70,000
| -11% | -$5.8M | 1.2% | 29 |
|
|
2020
Q2 | $50.6M | Sell |
646,841
-100,959
| -14% | -$6.68M | 1.39% | 19 |
|
|
2020
Q1 | $33.2M | Buy |
747,800
+47,800
| +7% | +$2.48M | 1.37% | 25 |
|
|
2019
Q4 | $29.9M | Buy |
700,000
+92,000
| +15% | +$3.8M | 0.94% | 42 |
|
|
2019
Q3 | $26M | Buy |
608,000
+28,000
| +5% | +$1.52M | 1.04% | 31 |
|
|
2019
Q2 | $36.8M | Hold |
580,000
| – | – | 1.33% | 21 |
|
|
2019
Q1 | $40.2M | Buy |
580,000
+155,000
| +36% | +$8.86M | 1.55% | 11 |
|
|
2018
Q4 | $18.5M | Buy |
425,000
+225,000
| +113% | +$12.3M | 0.87% | 35 |
|
|
2018
Q3 | $15.3M | Hold |
200,000
| – | – | 0.55% | 63 |
|
|
2018
Q2 | $15.4M | Buy |
200,000
+27,000
| +16% | +$1.74M | 0.59% | 65 |
|
|
2018
Q1 | $8.82M | Buy |
173,000
+10,000
| +6% | +$504K | 0.38% | 87 |
|
|
2017
Q4 | $7.56M | Hold |
163,000
| – | – | 0.34% | 87 |
|
|
2017
Q3 | $8.68M | Buy |
163,000
+2,500
| +2% | +$148K | 0.4% | 80 |
|
|
2017
Q2 | $9.97M | Buy |
160,500
+750
| +0.5% | +$45.2K | 0.5% | 62 |
|
|
2017
Q1 | $10.8M | Hold |
159,750
| – | – | 0.62% | 53 |
|
|
2016
Q4 | $11.2M | Buy |
159,750
+12,750
| +9% | +$905K | 0.75% | 44 |
|
|
2016
Q3 | $10.4M | Buy |
147,000
+5,500
| +4% | +$351K | 0.65% | 52 |
|
|
2016
Q2 | $6.92M | Buy |
141,500
+23,000
| +19% | +$1.49M | 0.51% | 61 |
|
|
2016
Q1 | $7.5M | Buy |
118,500
+13,000
| +12% | +$851K | 0.63% | 50 |
|
|
2015
Q4 | $11.8M | Sell |
105,500
-1,500
| -1% | -$150K | 0.9% | 37 |
|
|
2015
Q3 | $10.3M | Buy |
107,000
+15,000
| +16% | +$1.72M | 0.84% | 40 |
|
|
2015
Q2 | $9.42M | Hold |
92,000
| – | – | 0.69% | 50 |
|
|
2015
Q1 | $5.71M | Buy |
92,000
+21,000
| +30% | +$1.17M | 0.53% | 68 |
|
|
2014
Q4 | $3.12M | Buy |
71,000
+3,500
| +5% | +$160K | 0.36% | 78 |
|
|
2014
Q3 | $3.82M | Buy |
67,500
+2,000
| +3% | +$101K | 0.59% | 52 |
|
|
2014
Q2 | $2.94M | Buy |
65,500
+14,000
| +27% | +$576K | 0.53% | 65 |
|
|
2014
Q1 | $2.52M | Buy |
+51,500
| New | +$2.65M | 0.58% | 54 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Rock Springs Capital Management's RARE Position: Q1 2026 in Review
Rock Springs Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 3.8% in Q1 2026, selling an estimated $1.09M and leaving 1,218,773 shares worth $25.5M. The position accounts for 1.5% of the portfolio, ranked #20.
Rock Springs Capital Management first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $110M in Q3 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Rock Springs Capital Management held 1,218,773 shares of Ultragenyx Pharmaceutical worth $25.5M as of Q1 2026.
- Rock Springs Capital Management sold 48,468 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.09M.
- Ultragenyx Pharmaceutical made up 1.5% of Rock Springs Capital Management's portfolio in Q1 2026, its #20 holding.
- Rock Springs Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
- Rock Springs Capital Management's Ultragenyx Pharmaceutical position peaked at $110M in Q3 2024.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.